AGER and diabetic retinopathy: Inhibition of TAGE formation, blockade of TAGE-RAGE interactions, and the suppression of RAGE expression or its downstream pathways by the agents discussed here are promising novel therapeutic strategies for the treatment of patients with diabetic retinopathy.